HAYWARD, Calif., July 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated will announce its second quarter 2007 financial results on Thursday, August 2, 2007, after market close.
The announcement of Kosan's second quarter 2007 financial results will be followed by a conference call and live webcast on August 2, 2007 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Interested parties may access the live call by dialing 866.510.0676 (US) or 617.597.5361 (international), access code 92658383.
Interested parties may listen to the webcast live at http://www.kosan.com by clicking on the "Webcasts" tab under the heading, "Investors/Press."
The webcast is also being distributed over Thomson's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson's individual investor center at http://www.earnings.com or by visiting any of the investor sites in Thomson's Individual Investor Network. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents, at http://www.streetevents.com. A telephonic replay will be available through August 9, 2007 by dialing 888-286-8010, access code: 46389405. International callers can dial 617-801-6888, access code: 46389405.
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.
For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.
Kosan Biosciences IncorporatedCONTACT: Gary S. Titus, Chief Financial Officer, +1-510-731-5373,titus@kosan.com, or Jane M. Green, VP, Corporate Communications,+1-510-731-5335, mobile, +1-415-652-4819, green@kosan.com, both of KosanBiosciences Incorporated
Web site: http://www.kosan.com/
